Deans' stroke musings: Neuroprotective therapies: Preclinical reproducibility is only part of the problem

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, August 5, 2015

Neuroprotective therapies: Preclinical reproducibility is only part of the problem

The writer of this is the same person who talked on failed neuroprotective drugs. A quote from Dr. Michael Tymianskis' comment. on the 1000+ failed neuroprotection drugs.
Your doctor should be intimately acquainted with him and get the complete article. How else is your doctor keeping up-to-date?
http://stm.sciencemag.org/content/7/299/299fs32.abstract?

Michael Tymianski¹,²,³,⁴

+ Author Affiliations

E-mail: mike.tymianski@uhn.ca

Science Translational Medicine 05 Aug 2015:
Vol. 7, Issue 299, pp. 299fs32
DOI: 10.1126/scitranslmed.aac9412

You are currently viewing the abstract.
View Full Text

Abstract

Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).